OR WAIT null SECS
Hahn promises transparency in the review and approval of COVID-19 vaccines.
FDA announced the agency will hold a public meeting of the Vaccines and Related Biological Products Advisory Committee on Oct. 22, 2020 to discuss the development, authorization, and/or licensure of COVID-19 vaccines. The meeting is scheduled from 10 am–5 pm ET via webcast.
“The FDA has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee to address the general development of COVID-19 vaccines on October 22nd. The agency is also prepared to rapidly schedule additional meetings of this committee upon submission of any applications as appropriate,” said FDA Commissioner Stephen M. Hahn, in an Aug. 28, 2020 statement. “I want to assure the American people that the process and review for vaccine development will be as open and transparent as possible. A discussion with this committee, made up of outside scientific and public health experts from around the country, will help ensure clear public understanding regarding clinical development of these vaccines indicated to prevent COVID-19 and the data needed to facilitate their authorization or licensure. It is critical for people to see FDA’s expectations for data to support safety and effectiveness.”